Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Eph tumour suppression: the dark side of Gleevec

Nature Cell Biology volume 8, pages 785–786 (2006)Cite this article

Gleevec inhibits the oncogenic BCR–ABL tyrosine kinase in chronic myelogenous leukaemia and thus safely and effectively suppresses this human cancer. Gleevec also inhibits the normal cellular ABL, a downstream effector of the Eph-receptors, which mediate repulsive cell–cell interactions to regulate axon guidance, angiogenesis and epithelial homeostasis. New work shows that Eph-dependent tumour suppression requires ABL and is blocked by Gleevec, thus cautioning against the indiscriminate use of this drug in cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Tumour suppression by EphB4 receptor.

References

  1. Deininger, M., Buchdunger, E. & Druker, B. J. Blood 105, 2640–2653 (2005).

    Article  CAS  Google Scholar 

  2. Shah, N. P. et al. Cancer Cell 2, 117–125 (2002).

    Article  CAS  Google Scholar 

  3. Noren, N., Foos, G, Hauser, C. A., & Pasquale, E. B. Nature Cell Biol. 8, 815–825 (2006).

    Article  CAS  Google Scholar 

  4. Wang, J. Y. Nature Cell Biol. 6, 3–7 (2004).

    Article  CAS  Google Scholar 

  5. Wang, J. Y. Cell Res. 15, 43–48 (2005).

    Article  Google Scholar 

  6. Furstoss, O. et al. EMBO J. 21, 514–524 (2002).

    Article  CAS  Google Scholar 

  7. Pasquale, E. B. Nature Rev. Mol. Cell Biol. 6, 462–475 (2005).

    Article  CAS  Google Scholar 

  8. Clevers, H. & Batlle, E. Cancer Res. 66, 2–5 (2006).

    Article  CAS  Google Scholar 

  9. Holmberg, J. et al. Cell 125, 1151–1163 (2006).

    Article  CAS  Google Scholar 

  10. Macrae, M. et al. Cancer Cell 8, 111–118 (2005).

    Article  CAS  Google Scholar 

  11. Kain, K. H. & Klemke, R. L. J. Biol. Chem. 276, 16185–16192 (2001).

    Article  CAS  Google Scholar 

  12. Frasca, F., Vigneri, P., Vella, V., Vigneri, R. & Wang, J. Y. Oncogene 20, 3845–3856 (2001).

    Article  CAS  Google Scholar 

  13. Truong, T., Sun, G., Doorly, M., Wang, J. Y. & Schwartz, M. A. Proc. Natl Acad. Sci. USA 100, 10281–10286 (2003).

    Article  CAS  Google Scholar 

  14. Depaepe, V. et al. Nature 435, 1244–1250 (2005).

    Article  CAS  Google Scholar 

  15. Vigneri, P. & Wang, J. Y. Nature Med. 7, 228–234 (2001).

    Article  CAS  Google Scholar 

  16. Vella, V. et al. J. Biol. Chem. 278, 25151–25157 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, School of Medicine, La Jolla, 92093-0820, CA, USA

    Jean Y. J. Wang

Authors
  1. Jean Y. J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, J. Eph tumour suppression: the dark side of Gleevec. Nat Cell Biol 8, 785–786 (2006). https://doi.org/10.1038/ncb0806-785

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncb0806-785

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing